Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1917 1
1918 1
1950 1
1956 1
1959 1
1960 2
1961 3
1962 4
1963 9
1964 9
1965 6
1966 9
1967 8
1968 12
1969 10
1970 6
1971 9
1972 4
1973 6
1974 7
1975 13
1976 15
1977 18
1978 15
1979 23
1980 21
1981 20
1982 26
1983 31
1984 25
1985 29
1986 38
1987 49
1988 40
1989 55
1990 55
1991 45
1992 69
1993 47
1994 58
1995 56
1996 72
1997 75
1998 103
1999 110
2000 97
2001 92
2002 89
2003 108
2004 107
2005 119
2006 116
2007 121
2008 136
2009 137
2010 118
2011 149
2012 153
2013 170
2014 160
2015 182
2016 163
2017 171
2018 171
2019 179
2020 226
2021 278
2022 228
2023 197
2024 111
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

4,565 results

Results by year

Filters applied: . Clear all
Page 1
Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.
Nakayama Y, Onishi A, Yamamoto W, Yoshikawa A, Shiba H, Yoshida N, Son Y, Shirasugi I, Maeda T, Katsushima M, Hashimoto M, Etani Y, Itami T, Nozaki Y, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Matsuda S, Morinobu A. Nakayama Y, et al. Among authors: hashimoto m. Clin Exp Med. 2024 May 10;24(1):97. doi: 10.1007/s10238-024-01360-w. Clin Exp Med. 2024. PMID: 38727756 Free PMC article.
Factors associated with drug retention of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: A multicentre REVEAL cohort study.
Shiomi M, Watanabe R, Matsuda S, Kotani T, Okazaki A, Masuda Y, Yoshida T, Shoji M, Tsuge R, Kadoba K, Hiwa R, Yamamoto W, Takeda A, Itoh Y, Hashimoto M. Shiomi M, et al. Among authors: hashimoto m. Mod Rheumatol. 2024 May 10:roae044. doi: 10.1093/mr/roae044. Online ahead of print. Mod Rheumatol. 2024. PMID: 38727536
Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.
Watanabe R, Ebina K, Gon T, Okano T, Murata K, Murakami K, Maeda Y, Jinno S, Shirasugi I, Son Y, Amuro H, Katayama M, Hara R, Hata K, Yoshikawa A, Yamamoto W, Tachibana S, Hayashi S, Etani Y, Katsushima M, Fukumoto K, Yamada S, Hashimoto M. Watanabe R, et al. Among authors: hashimoto m. Rheumatology (Oxford). 2024 May 9:keae265. doi: 10.1093/rheumatology/keae265. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38724245
Energy landscape analysis and time-series clustering analysis of patient state multistability related to rheumatoid arthritis drug treatment: The KURAMA cohort study.
Yamamoto K, Sakaguchi M, Onishi A, Yokoyama S, Matsui Y, Yamamoto W, Onizawa H, Fujii T, Murata K, Tanaka M, Hashimoto M, Matsuda S, Morinobu A. Yamamoto K, et al. Among authors: hashimoto m. PLoS One. 2024 May 6;19(5):e0302308. doi: 10.1371/journal.pone.0302308. eCollection 2024. PLoS One. 2024. PMID: 38709812 Free PMC article.
4,565 results